Prognostic Value of Survivin in Locally Advanced Prostate Cancer: Study Based on RTOG 8610

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 4, 2009, Pages 1033-1042

  Zhang, Min ^a   Ho, Alex ^b   Hammond, Elizabeth H ^c   Suzuki, Yoshiyuki ^d   Bermudez, R Scott ^e   Lee, R Jeffrey ^c   Pilepich, Michael ^f   Shipley, William U ^a   Sandler, Howard ^g   Khor, Li Yan ^h   Pollack, Alan ^h   Chakravarti, Arnab ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b AMERICAN COLLEGE OF RADIOLOGY   (United States)

^c LDS HOSPITAL   (United States)

^d GUNMA UNIVERSITY   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h FOX CHASE CANCER CENTER   (United States)

Author keywords

Prognostic factor; Prostate cancer; Radiotherapy; Survivin

Indexed keywords

DECISION MAKING; DENSITY (OPTICAL); DENSITY MEASUREMENT (OPTICAL); RADIOTHERAPY; RISK ANALYSIS; TUMORS;

ANDROGEN DEPRIVATIONS; CONFIDENCE INTERVALS; HAZARD RATIOS; LOCALLY ADVANCED PROSTATE CANCERS; MULTI-VARIATE ANALYSIS; OPTICAL DENSITIES; OVER EXPRESSIONS; OVERALL SURVIVALS; PROGNOSTIC FACTOR; PROSTATE CANCER; RADIATION THERAPY ONCOLOGY GROUPS; RADIOTHERAPY ALONE; SPLICE VARIANTS; SUBCELLULAR COMPARTMENTS; SURVIVIN; UNIVARIATE ANALYSIS;

MULTIVARIANT ANALYSIS;

CYTOPLASM PROTEIN; NUCLEAR PROTEIN; SURVIVIN;

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; DIAGNOSTIC VALUE; DISEASE COURSE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OPTICAL DENSITY; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCORING SYSTEM;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL NUCLEUS; CLINICAL TRIALS, PHASE III AS TOPIC; CYTOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 61549127925     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.06.1489     Document Type: Article

References (50)

1. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
2. Salvesen G.S., and Duckett C.S. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3 (2002) 401-410
3. Kobayashi K., Hatano M., Otaki M., et al. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA 96 (1999) 1457-1462
4. Adida C., Crotty P.L., McGrath J., et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152 (1998) 43-49
5. Monzo M., Rosell R., Felip E., et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17 (1999) 2100-2104
6. Tanaka K., Iwamoto S., Gon G., et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6 (2000) 127-134
7. Kawasaki H., Altieri D.C., Lu C.D., et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58 (1998) 5071-5074
8. Lu C.D., Altieri D.C., and Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58 (1998) 1808-1812
9. Ikeguchi M., Ueta T., Yamane Y., et al. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res 8 (2002) 3131-3136
10. Chakravarti A., Noll E., Black P.M., et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20 (2002) 1063-1068
11. Chakravarti A., Zhai G.G., Zhang M., et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23 (2004) 7494-7506
12. Grossman D., McNiff J.M., Li F., et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113 (1999) 1076-1081
13. Zhang M., Mukherjee N., Bermudez R.S., et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 64 (2005) 293-302
14. Zhang M., Latham D.E., Delaney M.A., et al. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24 (2005) 2474-2482
15. McEleny K.R., Watson R.W., Coffey R.N., et al. Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 51 (2002) 133-140
16. Shariat S.F., Lotan Y., Saboorian H., et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100 (2004) 751-757
17. Kishi H., Igawa M., Kikuno N., et al. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 171 (2004) 1855-1860
18. Fortugno P., Wall N.R., Giodini A., et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115 (2002) 575-585
19. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3 (2003) 46-54
20. Badran A., Yoshida A., Ishikawa K., et al. Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun 314 (2004) 902-907
21. Mahotka C., Wenzel M., Springer E., et al. Survivin-deltaEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59 (1999) 6097-6102
22. Mahotka C., Liebmann J., Wenzel M., et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 9 (2002) 1334-1342
23. Mahotka C., Krieg T., Krieg A., et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100 (2002) 30-36
24. Noton E.A., Colnaghi R., Tate S., et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 281 (2006) 1286-1295
25. Caldas H., Jiang Y., Holloway M.P., et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24 (2005) 1994-2007
26. Kaur P., Kallakury B.S., Sheehan C.E., et al. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 128 (2004) 39-43
27. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
28. Khor L.Y., Desilvio M., Li R., et al. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. Int J Radiat Oncol Biol Phys 66 (2006) 25-30
29. Khor L.Y., Desilvio M., Al-Saleem T., et al. MDM2 as a predictor of prostate carcinoma outcome: An analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer 104 (2005) 962-967
30. Torres-Roca J.F., DeSilvio M., Mora L.B., et al. Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10. Urology 69 (2007) 505-509
31. Wicht H., Maronde E., Olcese J., et al. A semiquantitative image-analytical method for the recording of dose-response curves in immunocytochemical preparations. J Histochem Cytochem 47 (1999) 411-420
32. Kaplan E.L., and Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-816
33. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist (1988) 161141-161154
34. Shipley W.U., Desilvio M., Pilepich M.V., et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys 64 (2006) 1162-1167
35. Roach III M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26 (2008) 585-591
36. D'Amico A.V. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology 60 (2002) 32-38
37. Okada E., Murai Y., Matsui K., et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 163 (2001) 109-116
38. Kennedy S.M., O'Driscoll L., Purcell R., et al. Prognostic importance of survivin in breast cancer. Br J Cancer 88 (2003) 1077-1083
39. Trieb K., Lehner R., Stulnig T., et al. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 29 (2003) 379-382
40. Lehner R., Lucia M.S., Jarboe E.A., et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol 10 (2002) 134-138
41. Tonini G., Vincenzi B., Santini D., et al. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br J Cancer 92 (2005) 2225-2232
42. Fields A.C., Cotsonis G., Sexton D., et al. Survivin expression in hepatocellular carcinoma: Correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 17 (2004) 1378-1385
43. Ito T., Shiraki K., Sugimoto K., et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31 (2000) 1080-1085
44. Grabowski P., Kuhnel T., Muhr-Wilkenshoff F., et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 88 (2003) 115-119
45. Martinez A., Bellosillo B., Bosch F., et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164 (2004) 501-510
46. Falleni M., Pellegrini C., Marchetti A., et al. Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 200 (2003) 620-626
47. Ferrandina G., Legge F., Martinelli E., et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 92 (2005) 271-277
48. Honda R., Korner R., and Nigg E.A. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 14 (2003) 3325-3341
49. Tamm I., Wang Y., Sausville E., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58 (1998) 5315-5320
50. Krieg A., Mahotka C., Krieg T., et al. Expression of different survivin variants in gastric carcinomas: First clues to a role of survivin-2B in tumour progression. Br J Cancer 86 (2002) 737-743